

Draft Agenda and  
attendee list for the  
roundtable on long-term  
impacts of COVID.

Do you have any comments  
or changes?

If you are content we will  
issue invitations. [Joe]

OFFICIAL-SENSITIVE

## Secretary of State Roundtable

### Long-term impacts of COVID-19

15.00 – 16.00 via Microsoft Teams

Annex A

research into the long-term impacts of SARS-CoV-2 (COVID-

#### AGENDA

#### Objective:

To identify what research is required to investigate and mitigate the long-term impacts of COVID-19 on survivors.

Agenda Item	Time
<b>Welcome, introductions and aim</b> Secretary of State to set out the aims of the roundtable CMO/DCMO to set the clinical scene	15.00 – 15.05 (5 mins)
<b>Clinical issues and research needed to address them</b> <ul style="list-style-type: none"> <li>What evidence is needed on the longer-term impacts of COVID-19 and whether these impacts differ depending on the severity of the disease?</li> <li>What research is underway on post-hospitalisation cases? E.g. PHOSP-COVID</li> <li>What research is needed to look at longer term impacts on patients with initially milder disease who report prolonged or recurring symptoms?</li> <li>What could be learnt from studies on long-term impacts of SARS and MERS?</li> <li>What international trials are currently underway? E.g. CORAL study (USA study)</li> </ul>	15.05 – 15.20 (15 mins)
<b>Next steps and research design</b> Discussion of how to design research studies into the long-term impacts of COVID-19. Key questions to answer include: <ul style="list-style-type: none"> <li>Are additional clinical trials needed?</li> <li>How should we design studies for different levels of disease severity?</li> <li>How would individuals be recruited for these trials, particularly those who were asymptomatic or reported mild symptoms of the disease?</li> <li>Could research on longer-term impacts of COVID-19 be added to existing long-term cohort studies? E.g UK Biobank</li> </ul>	15.20 – 15.40 (20 mins)
<b>Other key questions or points to consider</b> <ul style="list-style-type: none"> <li>How this research would interface with initial treatment plans in a potential second wave given research will be in the early stages?</li> <li>Can digital approaches be used to enhance recruitment levels to trials rapidly?</li> <li>Are there any key interdependencies which we need to be aware of? E.g. with other workstreams</li> <li>Attendees given opportunity to raise other key considerations</li> </ul>	15.40 – 15.55 (15 mins)
<b>Summary and Next Steps</b> Secretary of State to summarise and set out key actions and next steps	15.55 – 16.00 (5 mins)